CNTB
Connect Biopharma Holdings Ltd
Next earnings Aug 17, 2026 · consensus $-1.90 EPS, $198K rev
Last earnings +14.5% on 2026-05-12
$2.19
▲ +5.80%$2.19▲ +124.62%
over 1Y
L $0.95EODHDH $3.69
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.8%
1W+10.1%
1M-8.8%
3M-36.5%
YTD-13.1%
1Y+124.6%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Conservative balance sheet (liabilities/equity 0.34x); but revenue fell -99.8% YoY.
Revenue (FY2025) $64.0K · FY2025
Connect Biopharma Holdings Ltd shows $64.0K in FY2025 revenue (-99.8% YoY), a -86687.5% net margin, and -132.2% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $0.00 | $26.0M | $64.0K |
| Gross profit | — | — | — |
| Operating income | -$69.1M | -$22.5M | -$58.1M |
| Net income | -$62.1M | -$15.6M | -$55.5M |
| Diluted EPS | -$1.13 | -$0.28 | -$1.00 |
| Net margin | — | -60.0% | -86687.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$85.4M
EV / EBITDA—
EV / Sales1334.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-44.8%
FCF yield-41.7%
Quality & risk
ROIC (est.)-109.3%
Free cash flow-$51.6M
Total debt—
Net cash$38.3M
Altman Z-Score-7.36 distress
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-05-292026-06-02open ↗EFFECTFiling2026-06-01open ↗SCHEDULE 13G/AFiling2026-05-15open ↗F-3Filing2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗8-KPeriod ending 2026-04-232026-04-23open ↗SCHEDULE 13GFiling2026-04-14open ↗4Period ending 2026-03-312026-04-02open ↗4Period ending 2026-03-312026-04-02open ↗4Period ending 2026-03-312026-04-01open ↗SCHEDULE 13D/AFiling2026-04-01open ↗
Frequently asked
- Is Connect Biopharma Holdings Ltd (CNTB) a buy?
- CNTB currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.34x); but revenue fell -99.8% YoY.
- What is Connect Biopharma Holdings Ltd's quality score?
- CNTB scores 30.450980392156858/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001835268, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:34:56 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.